If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
May 2012 660 Volume 11 • Issue 5
Copyright © 2012
CASE REPORT
Journal of Drugs in Dermatology
Treatment of Mild to Moderate Facial Melasma
With the Lumixyl Topical Brightening System
Basil M. Hantash MD PhDa and Felipe Jimenez PhDb
aElixir Institute of Regenerative Medicine, San Jose, CA
bEnvyMedical,Inc.,WestlakeVillage,CA
ABSTRACT
JDD
Background: Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A propri-
etary oligopeptide (LumixylTM) was previously shown to competitively inhibit mushroom and human tyrosinase in vitro without the
associated cytotoxicity of hydroquinone and to diminish the appearance of facial melasma.
Objective: The aim of this case study was to determine if the Lumixyl Topical Brightening System (0.01% oli
May 2012
661 Journal of Drugs in DerMatology May 2012 •
662 Journal of Drugs in DerMatology May 2012 •